| Identification | Back Directory | [Name]
Acetamide, N-[5-[4-[(4-chloro-3-fluorophenyl)methyl]-4,5-dihydro-6-methoxy-3,5-dioxo-1,2,4-triazin-2(3H)-yl]-2-fluorophenyl]- | [CAS]
1207440-88-7 | [Synonyms]
Acetamide, N-[5-[4-[(4-chloro-3-fluorophenyl)methyl]-4,5-dihydro-6-methoxy-3,5-dioxo-1,2,4-triazin-2(3H)-yl]-2-fluorophenyl]- | [Molecular Formula]
C19H15ClF2N4O4 | [MOL File]
1207440-88-7.mol | [Molecular Weight]
436.8 |
| Hazard Information | Back Directory | [Description]
ADX71441 is a GABAB positive allosteric modulator (PAM). ADX71441 increases urinary latencies and reduces the number of urinary events and the total and average urinary volumes. ADX71441 completely inhibits the micturition reflex and induced overflow incontinence in five out of 10 animals. GABAB PAM has potential as a novel approach for the treatment of overactive bladder. It may also mitigate alcoholism and have analgesic effects in the bladder. | [Uses]
ADX71441 is a potent and selective positive allosteric modulator of the GABAB receptor. ADX71441 is bioavailable after oral administration and is brain penetrant. ADX71441 has the potential for research of anxiety, pain and spasticity[1]. | [References]
[1] Kalinichev M, et al. The drug candidate, ADX71441, is a novel, potent and selective positive allosteric modulator of the GABAB receptor with a potential for treatment of anxiety, pain and spasticity. Neuropharmacology. 2017;114:34-47. DOI:10.1016/j.neuropharm.2016.11.016 |
|
|